Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment
- PMID: 35427530
- DOI: 10.1016/S2213-2600(21)00506-3
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment
Abstract
Chronic obstructive pulmonary disease (COPD) was traditionally thought to be caused by tobacco smoking. However, recognition of the importance of non-smoking-related risk factors for COPD has increased over the past decade, with evidence on the burden, risk factors, and clinical presentations of COPD in never-smokers. About half of all COPD cases worldwide are due to non-tobacco-related risk factors, which vary by geographical region. These factors include air pollution, occupational exposures, poorly controlled asthma, environmental tobacco smoke, infectious diseases, and low socioeconomic status. Impaired lung growth during childhood, caused by a range of early-life exposures, is associated with an increased risk of COPD. Potential mechanisms for the pathogenesis of COPD in never-smokers include inflammation, oxidative stress, airway remodelling, and accelerated lung ageing. Compared with smokers who develop COPD, never-smokers with COPD have relatively mild chronic respiratory symptoms, little or no emphysema, milder airflow limitation, and fewer comorbidities; however, exacerbations can still be frequent. Further research-including epidemiological, translational, clinical, and implementation studies-is needed to address gaps in understanding and to advance potential solutions to reduce the burden of COPD in never-smokers.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests IAY is a co-chair (unpaid) of the COPD-X Guidelines Committee of Lung Foundation Australia. CRJ reports receiving a grant to undertake an investigator-initiated clinical trial paid to her institution from GSK; consultancy fees from Novartis and AstraZeneca; honoraria for the development of educational materials from Boehringer Ingelheim, Novartis, and AstraZeneca; speaker's fees from Boehringer Ingelheim, Novartis, AstraZeneca, Cipla, and GSK; payment for expert testimony from Novartis and Chiesi; travel reimbursement from GSK, AstraZeneca, and Novartis; payment for advisory board membership and attendance at meetings from GSK, AstraZeneca, and Novartis; payment for attendance at meetings as a member of the National Dust Diseases Taskforce; and is chair (unpaid) of the board of Lung Foundation Australia and director (unpaid) of the Asbestos Diseases Research Institute. SSS is a member (unpaid) of the Board of Directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Comment in
-
GETting to know the many causes and faces of COPD.Lancet Respir Med. 2022 May;10(5):426-428. doi: 10.1016/S2213-2600(22)00049-2. Epub 2022 Apr 12. Lancet Respir Med. 2022. PMID: 35427529 No abstract available.
-
COPD, smoking, and social justice.Lancet Respir Med. 2022 May;10(5):428-430. doi: 10.1016/S2213-2600(22)00130-8. Epub 2022 Apr 12. Lancet Respir Med. 2022. PMID: 35427531 No abstract available.
-
Underappreciated causes of obstructive lung disease.Lancet Respir Med. 2023 Feb;11(2):e14. doi: 10.1016/S2213-2600(22)00527-6. Lancet Respir Med. 2023. PMID: 36731972 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous